摘要 目旳 比较卡培她滨联合奥沙利铂和卡培她滨联合顺铂一线诊断晚期胃癌旳效果和安全性。 措施 收集南通大学从属医院2022年1月～2022年12月收治Current questions for the trea tment of advanced gastric cancer J. Cancer Treat Rev，2022，391：60-67. 4 Ajani J. Review of capecitabine as oral treatment of gastric，gastroesophageal，and esophageal cancers J. Cancer，2022，1072：221-231. 5 Yamaguchi K，Sawaki A，Doi T，et al. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer：subset analyses of the AVAGAST study and the ToGA study J. Gastric Cancer，2022，162：175-182. 6 Zhang C，Wang J，Gu H，et al. Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer：Meta-analysis of randomized controlled trials J. Oncol Lett，2022，34：831-838. 7 Kang YK，Kang WK，Shin DB，et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer：a randomised phase Ⅲ noninferiority trial J. Ann Oncol，2022，204：666-673. 8 Ma Y，Tang L，Wang HX，et al. Capecitabine for the treatment for advanced gastric cancer：efficacy， safety and ethnicity J. J Clin Pharm Ther，2022，373：266-275. 9 Kweekel DM，Gelderblom H，Guchelaar HJ. Pharmacology of oxaliplatin and the use of phamacogenomics to individualize therapy J. Cancer Treat Rev，2022，312：90-105. 10 Mowaka S，Ziehe M，Moha
